Title: Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up
Version: 4 Date: 12 Jan 2023
Reviewer's report:
The authors discussed an important topic regarding HCV elimination and the importance to have
a strong database to follow up patients and to recall them when necessary. I'd like to mention
some points that i hope to be clarified:
Materials and Methods:
-Kindly define: poor medical status
-You mention that each patient received one of the 4 DAAs (elbasvir/grazoprevir, sofosbuvir/
ledipasvir, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir) therapy. Can you define the
selection criteria for each regimen or it was according to the availability?
Results:
-what was the main causes of refusal of therapy and from your point of view how could we
overcome this challenge?
Title: Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up
Version: 4 Date: 12 Jan 2023
Reviewer's report:
The authors discussed an important topic regarding HCV elimination and the importance to have
a strong database to follow up patients and to recall them when necessary. I'd like to mention
some points that i hope to be clarified:
Materials and Methods:
-Kindly define: poor medical status
-You mention that each patient received one of the 4 DAAs (elbasvir/grazoprevir, sofosbuvir/
ledipasvir, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir) therapy. Can you define the
selection criteria for each regimen or it was according to the availability?
Results:
-what was the main causes of refusal of therapy and from your point of view how could we
overcome this challenge?
Please review this paper.
user
Title: Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up
Version: 4 Date: 12 Jan 2023
Reviewer's report:
The authors discussed an important topic regarding HCV elimination and the importance to have
a strong database to follow up patients and to recall them when necessary. I'd like to mention
some points that i hope to be clarified:
Materials and Methods:
-Kindly define: poor medical status
-You mention that each patient received one of the 4 DAAs (elbasvir/grazoprevir, sofosbuvir/
ledipasvir, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir) therapy. Can you define the
selection criteria for each regimen or it was according to the availability?
Results:
-what was the main causes of refusal of therapy and from your point of view how could we
overcome this challenge?
assistant